About: Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.06 (-7.94%)
IMUASXImugene Ltd
Imugene Ltd share price
IMU price activity
Último preço
$ 0,060
Variação (24h)
-0,01 AUD (-7,94%)
Volume
2.37M
Volume (média 4 sem.)
-
Abertura
$ 0,06
Variação do dia
$ 0,06 - $ 0,06
Fechamento anterior
$ 0,06
Último negócio
10 Sep, 6:10 am GMT+0
Atrasado
10 Sep, 6:10 am GMT+0
IMU price performance
Atrasado
10 Sep, 6:10 am GMT+0
quote.marketSignals